½ÃÀ庸°í¼­
»óǰÄÚµå
1405904

½Ç½Ã°£ PCR(qPCR), µðÁöÅÐ PCR(dPCR) ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå ±Ô¸ð, Á¡À¯À² ¹× µ¿Ç⠺м® º¸°í¼­ : ±â¼úº°, Á¦Ç°º°, ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° µ¿Çâ(2024-2030³â)

Real-time PCR, Digital PCR, And End-point PCR Market Size, Share & Trends Analysis Report By Technology (Quantitative, Digital, End-point), By Product, By Application, By Region, And Segment Forecasts, 2024 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 120 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

½Ç½Ã°£ PCR(qPCR), µðÁöÅÐ PCR(dPCR) ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀåÀÇ ¼ºÀå ¹× µ¿Çâ :

Grand View Research, IncÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é Àü ¼¼°è ½Ç½Ã°£ PCR(qPCR), µðÁöÅÐ PCR(dPCR) ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå ±Ô¸ð´Â 2024³âºÎÅÍ 2030³â±îÁö 4.2%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù. 71¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±×·¯³ª Äڷγª19 ÆÒµ¥¹ÍÀÇ ¿µÇâÀ» Á¦¿ÜÇÑ ½ÇÁ¦ ¼¼°è ½Ç½Ã°£ PCR, µðÁöÅÐ PCR, ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀåÀº 2023³âºÎÅÍ 2030³â±îÁö 8.7%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)·Î È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. µðÁöÅÐ PCRÀº À¯»çÇÑ ´Ù¼öÀÇ ¼­¿­ÀÌ Á¸ÀçÇÒ ¶§ ¼Ò¼ö ¼­¿­À» Àý´ëÀûÀ¸·Î Á¤·®È­ÇÏ°í ºÐ¼®ÇÏ´Â »õ·Î¿î ±â¼úÀ̸ç, dPCRÀº Á¤È®ÇÏ°í ¹Î°¨ÇÑ ÇÙ»ê ÃøÁ¤À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¶ÇÇÑ, ½Ç½Ã°£ PCRÀº Áúº´ÀÇ Á¤È®ÇÑ Á¶±â Áø´ÜÀ» Á¦°øÇÏ¿© ½Å¼ÓÇϰí Á¤È®ÇÑ È¯ÀÚ Ä¡·á¸¦ Á¦°øÇÕ´Ï´Ù.

Æó¾Ï, Ç÷¾×¾Ï, ³úÁ¾¾ç°ú °°Àº Áúº´ Áõ°¡´Â ¼¼°è ½ÃÀå¿¡¼­ÀÇ Àû¿ë È®´ë¸¦ ÃËÁøÇϰí ÀÖÀ¸¸ç, Globocan 2020¿¡ µû¸£¸é Æó¾ÏÀº À¯·´¿¡¼­ µÎ ¹øÂ°·Î ÈçÇÑ ¾ÏÀ¸·Î 477,534°ÇÀÇ ½Å±Ô Áø´ÜÀ» ¹ÞÀº °ÍÀ¸·Î Ãß»êµË´Ï´Ù. ¶ÇÇÑ, ½Ç½Ã°£ ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ ¹× Á¤·®Àû ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ°ú °°Àº ±âÁ¸ ±â¼ú¿¡ ºñÇØ µðÁöÅÐ ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀÀÇ ÀåÁ¡Àº ¿¹Ãø ±â°£ µ¿¾È äÅÃÀ» ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¶ÇÇÑ, ½ÅÈï±¹ÀÇ ÀÇ·áºñ ÁöÃâ Áõ°¡¿Í Á¤È®ÇÑ ºÐÀÚ Áúȯ °ËÃâ¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϸ鼭 ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, Äڷγª19ÀÇ ´ëÀ¯ÇàÀ¸·Î ÀÎÇØ µðÁöÅÐ PCR Àåºñ¿Í ½Ã¾à¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, Äڷγª19 °¨¿°Àº ÃֽеðÁöÅÐ PCR Àåºñ¸¦ ÅëÇØ ºÐÀÚÁø´Ü ±â¼ú·Î °ËÃâµÇ°í ÀÖ½À´Ï´Ù. È®ÁøÀÚ°¡ ¹ß»ýÇß°í, ¾à 530¸¸ ¸íÀÌ »ç¸ÁÇÑ °ÍÀ¸·Î Áý°èµÆ½À´Ï´Ù. ¶ÇÇÑ Á¦¾à ¾÷°è¿¡¼­´Â µðÁöÅÐ PCR Àåºñ°¡ ¿¬±¸°³¹ß¿¡µµ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ±â¼ú ¹ßÀü°ú ¼¼°è ½ÃÀå¿¡¼­ÀÇ Á¦Ç° Ãâ½Ã Áõ°¡´Â ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2021³â 6¿ù Bio-Rad Laboratories, Inc.´Â Äڷγª19 Æó¼ö °Ë»ç¸¦ À§ÇÑ PREvalence ddPCR SARS-CoV-2 Æó¼ö Á¤·® ŰƮ Ãâ½Ã¸¦ ¹ßÇ¥Çß½À´Ï´Ù.

¶ÇÇÑ, ±â¼ú ¹ßÀüÀ» À§ÇÑ R&D ÇÁ·ÎÁ§Æ® Áõ°¡¿Í µðÁöÅÐ ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ °³¹ßÀ» À§ÇÑ ±â¾÷ °£ Çù·Â °ü°è Áõ°¡´Â PCR °Ë»çÀÇ È°¿ëÀ» Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, Ű¾ÆÁ¨Àº 2022³â 1¿ù Attila BioSystems &Actome GmbH¿Í Á¦ÈÞÇÏ¿© ºñħ½ÀÀû »êÀü°Ë»ç(NIPT) ±â¼úÀ» QIAGENÀÇ dPCR¿¡ Á¦°øÇÔÀ¸·Î½á QIAcuityÀÇ ¿ëµµ ¼ö¸¦ ´Ã¸®°í ÀÖ½À´Ï´Ù. ±× °á°ú, ½Ç½Ã°£ PCR ¹× µðÁöÅÐ PCR ±â¼úÀÇ »ç¿ëÀº ¿¹Ãø ±â°£ µ¿¾È Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½Ç½Ã°£ PCR(qPCR), µðÁöÅÐ PCR(dPCR) ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå º¸°í¼­ÀÇ ÁÖ¿ä ³»¿ë:

  • ±â¼úº°·Î´Â Á¤·®Àû PCR ºÎ¹®ÀÌ 2023³â 83.34% ÀÌ»óÀÇ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â Äڷγª19 ¼±º° ¹× Áø´ÜÀ» À§ÇÑ ½Ç½Ã°£ ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀÀ» ±â¹ÝÀ¸·Î ÇÑ Á¦Ç° µµÀÔ Áö¿ø ±â¼úÀÇ ³ôÀº äÅÿ¡ ±âÀÎÇÕ´Ï´Ù.
  • ¼Ò¸ðǰ ¹× ½Ã¾à ºÎ¹®Àº Á¶±â ¹ß°ß¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í µðÁöÅÐ PCR ¼Ò¸ðǰ ¹× ½Ã¾àÀ» Á¦Á¶ÇÏ´Â ÁÖ¿ä ±â¾÷ÀÇ ¼ö·Î ÀÎÇØ 2023³â 62.62% ÀÌ»óÀÇ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • ºÏ¹Ì´Â ³ôÀº R&D ÅõÀÚÀÇ Á¸Àç, ±â¼úÀûÀ¸·Î Áøº¸µÈ ÇコÄÉ¾î ¿¬±¸ ÇÁ·¹ÀÓ¿öÅ©ÀÇ °¡¿ë¼º, Àú¸íÇÑ ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ Á¦Á¶¾÷üÀÇ °­·ÂÇÑ Á¸Àç, ÀÌ Áö¿ªÀÇ ½Å¼ÓÇÑ Áø´Ü Å×½ºÆ®¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ 2023³â 35.94% ÀÌ»óÀÇ ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÏ¸ç ½ÃÀåÀ» Àå¾ÇÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

    ¸ñÂ÷

    Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

    Á¦2Àå ÁÖ¿ä ¿ä¾à

    Á¦3Àå ½Ç½Ã°£ PCR(qPCR), µðÁöÅÐ PCR(dPCR) ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå - ¾÷°è Àü¸Á

    • ½ÃÀå °èÅë Àü¸Á
    • ½ÃÀå ¿ªÇÐ
    • ºñ±³ ÇØ¼®
    • SWOT ºÐ¼®, ¿äÀκ°(Á¤Ä¡¡¤¹ý·ü, °æÁ¦¡¤±â¼ú)
    • ¾÷°è ºÐ¼® - PorterÀÇ Five Forces ºÐ¼®

    Á¦4Àå ½Ç½Ã°£ PCR(qPCR), µðÁöÅÐ PCR(dPCR) ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå ºÐ¼®, ±â¼ú ¹üÀ§, 2018³â-2030³â

    • ½Ç½Ã°£ PCR(qPCR), µðÁöÅÐ PCR(dPCR) ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå : ±â¼ú º¯µ¿ ºÐ¼®
    • Á¤·®Àû
      • Á¤·®ÀûÀÎ ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018³â-2030³â
      • ¼Ò¸ðǰ ¹× ½Ã¾à
      • ±â±â
      • ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º
    • µðÁöÅÐ
      • µðÁöÅÐ ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018³â-2030³â
      • ¼Ò¸ðǰ ¹× ½Ã¾à
      • ±â±â
      • ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º
    • ¿£µåÆ÷ÀÎÆ® PCR
      • ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018³â-2030³â
      • ¼Ò¸ðǰ ¹× ½Ã¾à
      • ±â±â
      • ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º

    Á¦5Àå ½Ç½Ã°£ PCR(qPCR), µðÁöÅÐ PCR(dPCR) ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå ºÐ¼®, Á¦Ç° ¹üÀ§, 2018³â-2030³â

    • ½Ç½Ã°£ PCR(qPCR), µðÁöÅÐ PCR(dPCR) ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå : Á¦Ç° º¯µ¿ ºÐ¼®
    • ¼Ò¸ðǰ ¹× ½Ã¾à
      • ¼Ò¸ðǰ ¹× ½Ã¾à ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018³â-2030³â
    • ±â±â
      • ±â±â ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018³â-2030³â
    • ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º
      • ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018³â-2030³â

    Á¦6Àå ½Ç½Ã°£ PCR(qPCR), µðÁöÅÐ PCR(dPCR) ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå ºÐ¼®, ¿ëµµ, 2018³â-2030³â

    • ½Ç½Ã°£ PCR(qPCR), µðÁöÅÐ PCR(dPCR) ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå : ¿ëµµ º¯µ¿ ºÐ¼®
    • ÀÓ»ó
      • ÀÓ»ó ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018³â-2030³â
      • º´¿øÃ¼ °Ë»ç
      • Á¾¾çÇÐ °Ë»ç
      • Ç÷¾×°Ë»ç
      • ¾×ü »ý°Ë °Ë»ç
      • DPCR ±â¹Ý ºñħ½ÀÀû »êÀü °Ë»ç(Nipt)
      • ±âŸ
    • ¿¬±¸
      • ½ÃÀå Ã߻ꡤ¿¹Ãø, 2018³â-2030³âÀ» Á¶»ç
      • Áٱ⼼Æ÷ Á¶»ç
      • DNA Ŭ·Î´× ¹× ¹è¿­ °áÁ¤
      • ÀçÁ¶ÇÕ DNA ±â¼ú
      • Èñ±Í µ¹¿¬º¯ÀÌ Å½Áö
      • À¯ÀüÀÚ ¹ßÇö
      • ´Ü¼¼Æ÷ ºÐ¼®
      • ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ºÐ¼®
      • Ä«ÇǼö º¯È­ ºÐ¼®
      • ¶óÀ̺귯¸® Á¤·®È­(NG)
      • mrna ¹× mirna ¹ßÇö
      • Á¾ ½Äº°
      • GMO ŽÁö
    • ¹ýÀÇÇÐ ¹× ±âŸ

    Á¦7Àå ½Ç½Ã°£ PCR(qPCR), µðÁöÅÐ PCR(dPCR) ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå ºÐ¼®, Áö¿ª, 2018³â-2030³â

    • ±¹°¡º° ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â ¹× 2030³â
      • ºÏ¹Ì
      • À¯·´
      • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • ¶óƾ¾Æ¸Þ¸®Ä«
      • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

    Á¦8Àå ½Ç½Ã°£ PCR(qPCR), µðÁöÅÐ PCR(dPCR) ¹× ¿£µåÆ÷ÀÎÆ® PCR ½ÃÀå - °æÀï ±¸µµ

    • ±â¾÷ ºÐ·ù
    • Àü·« ¸ÅÇÎ
      • ½ÅÁ¦Ç° ¹ß¸Å
      • ÆÄÆ®³Ê½Ê
      • Ãëµæ
      • Çù¾÷
      • ÀÚ±ÝÁ¶´Þ
    • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
    • ±â¾÷ °³¿ä
      • Abbott
      • Qiagen
      • Bio-Rad Laboratories, Inc.
      • Agilent Technologies, Inc.
      • Thermo Fisher Scientific, Inc.
      • Ge Healthcare
      • Biomerieux Sa
      • F. Hoffmann-La Roche Ltd
      • Fluidigm Corporation
    LSH 24.01.26

    Real-time PCR, Digital PCR, And End-point PCR Market Growth & Trends:

    The global real-time PCR, digital PCR, and end-point PCR market size is expected to reach USD 7.18 billion by 2030, registering a CAGR of 4.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. However, the real global real-time PCR, digital PCR, and end-point PCR market without the impact of the COVID-19 pandemic is expected to expand at a compound annual growth rate (CAGR) of 8.7% from 2023 to 2030. Digital PCR is a novel technique for absolute quantification and analysis of minority sequences in the presence of similar majority sequences. dPCR allows for precise and sensitive nucleic acid measurement. In addition, real-time PCR provides precise and early diagnosis of diseases and rapid and targeted patient care hence anticipated to increase the demand in the coming years

    The rise in the occurrence of diseases such as lung cancer, blood cancer, and brain tumors is fueling the application expansion of the global market. According to Globocan 2020, lung cancer is the second most common cancer in Europe, with an estimated 477,534 newly diagnosed cases. Furthermore, the benefits of digital polymerase chain reaction over traditional technologies such as real-time and quantitative polymerase chain reaction are likely to drive adoption throughout the forecast period. Moreover, rising healthcare expenditures in emerging nations and the increased need for accurate molecular disease detection are propelling the market growth.

    Furthermore, the COVID-19 pandemic has increased the demand for digital PCR instruments and reagents. COVID-19 infections are detected using modern digital PCR instruments as a molecular diagnosis technique. According to the WHO, around 273 million cases have been diagnosed and roughly 5.3 million deaths have been documented worldwide due to COVID-19 as of December 2021. Moreover, in the pharmaceutical industry, digital PCR machines are also employed in R&D.

    Furthermore, advancements in technology and an increase in the number of product launches in the global market are expected to support the market growth. For instance, in June 2021, Bio-Rad Laboratories, Inc. announced the release of the PREvalence ddPCR SARS-CoV-2 waste-water quantifying kit for COVID-19 wastewater screening.

    Additionally, the increase in R&D projects for advancements in technology and an increase in collaborations between firms for the development of digital polymerase chain reactions are expected to increase the usage of PCR testing. For instance, Qiagen partnered with Atila BioSystems & Actome GmbH in January 2022 to deliver non-invasive prenatal testing (NIPT) technologies to QIAGEN's dPCR for a growing number of applications for QIAcuity. As a result, the usage of real-time and digital PCR technologies is projected to increase during the forecast period.

    Real-time PCR, Digital PCR, And End-point PCR Market Report Highlights:

    • By technology, the Quantitative PCR segment held largest revenue share of over 83.34% in 2023. This is attributed to the high adoption of technology supported by the introduction of products based on real-time polymerase chain reaction for screening and diagnosis of COVID-19
    • The consumables and reagents segment held the largest revenue share of over 62.62% in 2023 due to the increased demand for earlier detection and the number of significant companies manufacturing digital PCR consumables and reagents
    • North America dominated the market with a revenue share of over 35.94% in 2023 due to the presence of high R&D investment, the availability of a technologically advanced healthcare research framework, the strong presence of prominent polymerase chain reaction manufacturers, and an expanding requirement for rapid diagnostic tests in the region

    Table of Contents

    Chapter 1 Methodology and Scope

    • 1.1 Market Segmentation
      • 1.1.1 Product Segment
      • 1.1.2 Technology Segment
      • 1.1.3 Application Segment
    • 1.2 Regional Scope
    • 1.3 Estimates And Forecast Timeline
    • 1.4 Objectives
      • 1.4.1 Objective - 1
      • 1.4.2 Objective - 2
      • 1.4.3 Objective - 3
    • 1.5 Research Methodology
    • 1.6 Information Procurement
      • 1.6.1 Purchased Database
      • 1.6.2 Gvr's Internal Database
      • 1.6.3 Secondary Sources
      • 1.6.4 Primary Research
    • 1.7 Information Or Data Analysis
      • 1.7.1 Data Analysis Models
    • 1.8 Market Formulation & Validation
    • 1.9 Model Details
      • 1.9.1 Commodity Flow Analysis
    • 1.10 List of Secondary Sources
    • 1.11 List of Abbreviations

    Chapter 2 Executive Summary

    • 2.1 Market Summary
    • 2.2 Segment Snapshot
    • 2.3 Competitive Landscape Snapshot

    Chapter 3 Real-time PCR (qPCR) Market - Industry Outlook

    • 3.1 Market Lineage Outlook
      • 3.1.1 Parent Market Lineage Outlook
      • 3.1.2 Related/Ancillary Market Outlook
    • 3.2 Market Dynamics
      • 3.2.1 Market Drivers
        • 3.2.1.1 Rising incidence of chronic diseases, infectious diseases, and genetic disorders
        • 3.2.1.2 Technological advancements in PCR
        • 3.2.1.3 Implementation of MIQE guidelines
        • 3.2.1.4 Increasing demand for rapid diagnostic tests and growing adoption of qPCR & dPCR technologies
        • 3.2.1.5 Increasing number of CROs and forensic & research laboratories
        • 3.2.1.6 Increasing demand for prenatal genetic testing procedures
      • 3.2.2 Market Restraint Analysis
        • 3.2.2.1 High device costs associated with Real time PCR (qPCR)
        • 3.2.2.2 Stringent regulatory policies
    • 3.3 Comparative Analysis
    • 3.4 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
    • 3.5 Industry Analysis - Porter's

    Chapter 4 Real-time PCR (qPCR), end point PCR, and dPCR Market Analysis, Technology Scope, 2018 - 2030 (Revenue, USD Million)

    • 4.1 Real-time PCR (qPCR), end point PCR, and dPCR Market: Technology Movement Analysis
    • 4.2 Quantitative
      • 4.2.1 Quantitative Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 4.2.2 Consumables & Reagents
        • 4.2.2.1 Consumables & Reagents Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 4.2.3 Instruments
        • 4.2.3.1 Instruments Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 4.2.4 Software & Services
        • 4.2.4.1 Software & Services Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 4.3 Digital
      • 4.3.1 Digital Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 4.3.2 Consumables & Reagents
        • 4.3.2.1 Consumables & Reagents Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 4.3.3 Instruments
        • 4.3.3.1 Instruments Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 4.3.4 Software & Services
        • 4.3.4.1 Software & Services Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 4.4 End-Point Pcr
      • 4.4.1 End-Point Pcr Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 4.4.2 Consumables & Reagents
        • 4.4.2.1 Consumables & Reagents Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 4.4.3 Instruments
        • 4.4.3.1 Instruments Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 4.4.4 Software & Services
        • 4.4.4.1 Software & services market estimates and forecast, 2018 - 2030 (USD Million)

    Chapter 5 Real-time PCR (qPCR), end point PCR, and dPCR Market Analysis, Product Scope, 2018 - 2030 (Revenue, USD Million)

    • 5.1 Real-time PCR (qPCR), end point PCR, and dPCR Market: Products Movement Analysis
    • 5.2 Consumables & Reagents
      • 5.2.1 Consumables & Reagents Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.3 Instruments
      • 5.3.1 Instruments Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.4 Software & Services
      • 5.4.1 Software & Services Market Estimates And Forecast, 2018 - 2030 (USD Million)

    Chapter 6 Real-time PCR (qPCR), end point PCR, and dPCR Market Analysis, Application Scope, 2018 - 2030 (Revenue, USD Million)

    • 6.1 Real-time PCR (qPCR), end point PCR, and dPCR Market: Application Movement Analysis
    • 6.2 Clinical
      • 6.2.1 Clinical Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 6.2.2 Pathogen Testing
        • 6.2.2.1 Pathogen Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 6.2.3 Oncology Testing
        • 6.2.3.1 Oncology Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 6.2.4 Blood Screening
        • 6.2.4.1 Blood Screening Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 6.2.5 Liquid Biopsy Testing
        • 6.2.5.1 Liquid Biopsy Testing Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 6.2.6 Dpcr-Based Non-Invasive Prenatal Testing (Nipt)
        • 6.2.6.1 Dpcr-Based Non-Invasive Prenatal Testing (Nipt) Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 6.2.7 Others
        • 6.2.7.1 Others Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.3 Research
      • 6.3.1 Research Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 6.3.2 Stem Cell Research
        • 6.3.2.1 Stem Cell Research Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 6.3.3 Dna Cloning & Sequencing
        • 6.3.3.1 Dna Cloning & Sequencing Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 6.3.4 Recombinant Dna Technology
        • 6.3.4.1 Recombinant Dna Technology Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 6.3.5 Rare Mutation Detection
        • 6.3.5.1 Rare Mutation Detection Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 6.3.6 Gene Expression
        • 6.3.6.1 Gene Expression Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 6.3.7 Single-Cell Analysis
        • 6.3.7.1 Single-Cell Analysis Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 6.3.8 Microbiome Analysis
        • 6.3.8.1 Microbiome Analysis Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 6.3.9 Copy Number Variation Analysis
        • 6.3.9.1 Copy Number Variation Analysis Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 6.3.10 Library Quantification (Ngs)
        • 6.3.10.1 Library Quantification (Ngs) Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 6.3.11 Characterization Of Low-Fold Changes In Mrna And Mirna Expression
        • 6.3.11.1 Characterization Of Low-Fold Changes In Mrna And Mirna Expression Market Estimates And Forecast, 2018 - 2030 (USD Million)
      • 6.3.12 Species Identification
        • 6.3.12.1 Species identification market estimates and forecast, 2018 - 2030 (USD Million)
      • 6.3.13 GMO Detection
        • 6.3.13.1 GMO detection market estimates and forecast, 2018 - 2030 (USD Million)
    • 6.4 Forensics and Others
        • 6.4.1.1 Forensics and others market estimates and forecast, 2018 - 2030 (USD Million)

    Chapter 7 Real-time PCR (qPCR), end point PCR, and dPCR Market Analysis, Regional Scope, 2018 - 2030 (Revenue, USD Million)

    • 7.1 Market Share Analysis by Country, 2023 & 2030
      • 7.1.1 North America
        • 7.1.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.1.2 U.S.
        • 7.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.1.2.2 Key country dynamics
        • 7.1.1.2.3 Competitive scenario
        • 7.1.1.2.4 Regulatory framework
        • 7.1.1.3 Canada
        • 7.1.1.3.1 Canada market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.1.3.2 Key country dynamics
        • 7.1.1.3.3 Competitive scenario
        • 7.1.1.3.4 Regulatory framework
      • 7.1.2 Europe
        • 7.1.2.1 Europe market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.2.2 UK
        • 7.1.2.2.1 UK market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.2.2.2 Key country dynamics
        • 7.1.2.2.3 Competitive scenario
        • 7.1.2.2.4 Regulatory framework
        • 7.1.2.3 Germany
        • 7.1.2.3.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.2.3.2 Key country dynamics
        • 7.1.2.3.3 Competitive scenario
        • 7.1.2.3.4 Regulatory framework
        • 7.1.2.4 France
        • 7.1.2.4.1 France market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.2.4.2 Key country dynamics
        • 7.1.2.4.3 Competitive scenario
        • 7.1.2.4.4 Regulatory framework
        • 7.1.2.5 Italy
        • 7.1.2.5.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.2.5.2 Key country dynamics
        • 7.1.2.5.3 Competitive scenario
        • 7.1.2.5.4 Regulatory framework
        • 7.1.2.6 Spain
        • 7.1.2.6.1 Spain market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.2.6.2 Key country dynamics
        • 7.1.2.6.3 Competitive scenario
        • 7.1.2.6.4 Regulatory framework
        • 7.1.2.7 Denmark
        • 7.1.2.7.1 Denmark market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.2.7.2 Key country dynamics
        • 7.1.2.7.3 Competitive scenario
        • 7.1.2.7.4 Regulatory framework
        • 7.1.2.8 Sweden
        • 7.1.2.8.1 Sweden market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.2.8.2 Key country dynamics
        • 7.1.2.8.3 Competitive scenario
        • 7.1.2.8.4 Regulatory framework
        • 7.1.2.9 Norway
        • 7.1.2.9.1 Norway market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.2.9.2 Key country dynamics
        • 7.1.2.9.3 Competitive scenario
        • 7.1.2.9.4 Regulatory framework
      • 7.1.3 Asia-Pacific
        • 7.1.3.1 Asia-Pacific market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.3.2 Japan
        • 7.1.3.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.3.2.2 Key country dynamics
        • 7.1.3.2.3 Competitive scenario
        • 7.1.3.2.4 Regulatory framework
        • 7.1.3.3 India
        • 7.1.3.3.1 India market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.3.3.2 Key country dynamics
        • 7.1.3.3.3 Competitive scenario
        • 7.1.3.3.4 Regulatory framework
        • 7.1.3.4 Australia
        • 7.1.3.4.1 Australia market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.3.4.2 Key country dynamics
        • 7.1.3.4.3 Competitive scenario
        • 7.1.3.4.4 Regulatory framework
        • 7.1.3.5 China
        • 7.1.3.5.1 China market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.3.5.2 Key country dynamics
        • 7.1.3.5.3 Competitive scenario
        • 7.1.3.5.4 Regulatory framework
        • 7.1.3.6 South Korea
        • 7.1.3.6.1 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.3.6.2 Key country dynamics
        • 7.1.3.6.3 Competitive scenario
        • 7.1.3.6.4 Regulatory framework
        • 7.1.3.7 Thailand
        • 7.1.3.7.1 Thailand market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.3.7.2 Key country dynamics
        • 7.1.3.7.3 Competitive scenario
        • 7.1.3.7.4 Regulatory framework
      • 7.1.4 Latin America
        • 7.1.4.1 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.4.2 Brazil
        • 7.1.4.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.4.2.2 Key country dynamics
        • 7.1.4.2.3 Competitive scenario
        • 7.1.4.2.4 Regulatory framework
        • 7.1.4.3 Mexico
        • 7.1.4.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.4.3.2 Key country dynamics
        • 7.1.4.3.3 Competitive scenario
        • 7.1.4.3.4 Regulatory framework
        • 7.1.4.4 Argentina
        • 7.1.4.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.4.4.2 Key country dynamics
        • 7.1.4.4.3 Competitive scenario
        • 7.1.4.4.4 Regulatory framework
      • 7.1.5 Middle East & Africa
        • 7.1.5.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.5.2 South Africa
        • 7.1.5.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.5.2.2 Key country dynamics
        • 7.1.5.2.3 Competitive scenario
        • 7.1.5.2.4 Regulatory framework
        • 7.1.5.3 Saudi Arabia
        • 7.1.5.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.5.3.2 Key country dynamics
        • 7.1.5.3.3 Competitive scenario
        • 7.1.5.3.4 Regulatory framework
        • 7.1.5.4 UAE
        • 7.1.5.4.1 UAE market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.5.4.2 Key country dynamics
        • 7.1.5.4.3 Competitive scenario
        • 7.1.5.4.4 Regulatory framework
        • 7.1.5.5 Kuwait
        • 7.1.5.5.1 Kuwait market estimates and forecast, 2018 - 2030 (USD Million)
        • 7.1.5.5.2 Key country dynamics
        • 7.1.5.5.3 Competitive scenario
        • 7.1.5.5.4 Regulatory framework

    Chapter 8 Real-time PCR (qPCR), end point PCR, and dPCR Market - Competitive Landscape

    • 8.1 Company Categorization
    • 8.2 Strategy Mapping
      • 8.2.1 New Product Launch
      • 8.2.2 Partnerships
      • 8.2.3 Acquisition
      • 8.2.4 Collaboration
      • 8.2.5 Funding
    • 8.3 Key Company Market Share Analysis, 2023
    • 8.4 Company Profiles
      • 8.4.1 Abbott
        • 8.4.1.1 Company Overview
        • 8.4.1.2 Financial Performance
        • 8.4.1.3 Product Benchmarking
        • 8.4.1.4 Strategic Initiatives
      • 8.4.2 Qiagen
        • 8.4.2.1 Company Overview
        • 8.4.2.2 Financial Performance
        • 8.4.2.3 Product Benchmarking
        • 8.4.2.4 Strategic Initiatives
      • 8.4.3 Bio-Rad Laboratories, Inc.
        • 8.4.3.1 Company Overview
        • 8.4.3.2 Financial Performance
        • 8.4.3.3 Product Benchmarking
        • 8.4.3.4 Strategic Initiatives
      • 8.4.4 Agilent Technologies, Inc.
        • 8.4.4.1 Company Overview
        • 8.4.4.2 Financial Performance
        • 8.4.4.3 Product Benchmarking
        • 8.4.4.4 Strategic Initiatives
      • 8.4.5 Thermo Fisher Scientific, Inc.
        • 8.4.5.1 Company Overview
        • 8.4.5.2 Affymetrix
        • 8.4.5.3 Company Overview
        • 8.4.5.4 Financial Performance
        • 8.4.5.5 Product Benchmarking
        • 8.4.5.6 Strategic Initiatives
      • 8.4.6 Ge Healthcare
        • 8.4.6.1 Company Overview
        • 8.4.6.2 Financial Performance
        • 8.4.6.3 Product Benchmarking
        • 8.4.6.4 Strategic Initiatives
      • 8.4.7 Biomerieux Sa
        • 8.4.7.1 Company Overview
        • 8.4.7.2 Financial Performance
        • 8.4.7.3 Product Benchmarking
        • 8.4.7.4 Strategic Initiatives
      • 8.4.8 F. Hoffmann-La Roche Ltd
        • 8.4.8.1 Company Overview
        • 8.4.8.2 Financial Performance
        • 8.4.8.3 Product Benchmarking
        • 8.4.8.4 Strategic Initiatives
      • 8.4.9 Fluidigm Corporation
        • 8.4.9.1 Company Overview
        • 8.4.9.2 Financial Performance
        • 8.4.9.3 Product Benchmarking
        • 8.4.9.4 Strategic Initiatives
  • ºñ±³¸®½ºÆ®
    0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
    »óǰ ºñ±³Çϱâ
    Àüü»èÁ¦